Drospirenone-containing contraception: curative and preventive aspects of use


Cite item

Full Text

Abstract

The use of combined hormonal contraceptives is a pathogenetically sound method of treating pathological conditions associated with the menstrual cycle. The study, the purpose of which was to study the effectiveness and acceptability of hormonal microdosed combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone (Yaz®, Bayer HealthCare Pharmaceuticals, Germany), in the treatment of women who suffer from premenstrual syndrome manifestations and of moderate to severe dysmenorrhea. As a result of treatment revealed a statistically significant reduction of the symptoms of premenstrual syndrome, in the absence of serious adverse effects.The study showed high efficacy and acceptability of a microdosed drospirenone-containing combined oral contraceptive in 24/4 mode for the treatmentof women with premenstrual syndrome secondary to severe.

About the authors

A V Ledina

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва

Email: antoninaledina@mail.ru
канд. мед. наук, врач акушер-гинеколог научно-поликлинического отд-ния

V N Prilepskaya

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва

д-р мед. наук, проф., зам. дир. по науч. работе, рук. научно-поликлинического отд-ния

References

  1. Прилепская В.Н. и др. Лечебные возможности современной гормональной контрацепции. Акцент на дроспиренонсодержащее соединение с новым режимом дозирования. Гинекология. 2012; 14 (1): 42-5.
  2. Machado R.B et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19-30.
  3. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67 (5): 647-55.
  4. Rapkin A.J, Sorger S.N, Winer S.A. Drospirenone/ethinyl estradiol. Drugs Today (Barc) 2008; 44 (2): 133-45.
  5. Pinkerton J.V. The menstrual cycle - mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24-9.
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
  7. Kim J, Kim D.H, Lee B.H et al. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 2009; 63 (19): 1057-64.
  8. Zhang S et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281 (17): 1632-7.
  9. D’Anci K.E, Rosenberg I.H. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 2004; 7 (6): 659-64.
  10. Moat S.J et al. High - but not low - dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36 (12): 850-9.
  11. Cagnacci A, Cannoletta M, Volpe A. High - dose short - term folate administration modifies ambulatory blood pressure in postmenopausal women. A placebo - controlled study. Eur J Clin Nutr 2009; 63 (10): 1266-8.
  12. Bottiglieri T, Reynolds E.H. Folate and neurological disease - basic mechanisms. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 355-72.
  13. Morris M.S, Jacques P. Folate and neurological function - epidemiological perspective. In: L.B.Bailey, editor. Folate in Health and Disease. CRC press; New York, NY, USA, 2010; p. 325-46.
  14. Arth A et al. Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect - United States, 1997-2009. MMWR Morb Mortal Wkly Rep 2015; 64 (1): 6-9.
  15. Hovdenak N, Haram K. Influence of mineral and vitamin supplements on pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2012; 164 (2): 127-32.
  16. Dunson D.B, Baird D.D, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004; 103 (1): 51-6.
  17. Holzgreve W et al. Addingfolate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonat Med 2012; 25 (9): 1529-36.
  18. Прилепская В.Н., Иванова Е.В., Бостанджян Л.Л. Контрацепция с фолатами - новые возможности профилактики пороков развития плода. Гинекология. 2013; 15 (1): 22-4.
  19. Czeizel A.E, Dudas I. Prevention of the first occurrence of neural - tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-5.
  20. Choi J.H еt al. Contemporary issues surrounding folic Acid fortification initiatives. Prev Nutr Food Sci 2014; 19 (4): 247-60.
  21. Talaulikar V.S, Arulkumaran S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66 (4): 240-7.
  22. Wang Y et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr advance online publication, January 28, 2015; doi: 10.1038/ejcn. 2014. 295.
  23. Hao N et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country. A retroprospective survey in China. Epilepsy Behav 2015; 22 (44C): 27-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).